Today, scientists presented final results from our Phase I clinical trial of ALN-TTRo1 at the XIII International Symposium on Amyloidosis held in Groningen. Data from this study show that administration of ALN-TTR01 resulted in statistically significant reductions in serum TTR protein levels, including both wild-type and mutant TTR protein, in ATTR patients. Knockdown of TTR, the disease-causing protein, was found to be dose dependent, rapid, and durable after just a single dose.
View our presentation (842 KB PDF) View our release Listen to KOL, Dr. Hawkins discuss the ALN-TTR program (recorded Jan. 2012) (27.7MB MP3)Posts Tagged with: 5×15
April 20, 2012
Positive Clinical Results for ALN-PCS, Reported at ATVB 2012
Yesterday, scientists presented positive results from our Phase I clinical trial of ALN-PCS at the American Heart Association’s Arteriosclerosis, Thrombosis and Vascular Biology 2012 Scientific Sessions held in Chicago. Results showed that administration of a single dose of ALN-PCS, in the absence of concomitant lipid-lowering agents such as statins, resulted in statistically significant and durable reductions of PCSK9 plasma levels of up to 84% and lowering of LDL-C of up to 50%.
View our presentation (572 KB PDF) View our release (572 KB PDF)January 4, 2012
ALN-PCS Preliminary Phase I Clinical Results
In January 2012, we presented positive preliminary data from our ALN-PCS Phase I study at Brigham and Women’s Hospital in Boston. Data show that ALN-PCS demonstrated robust, statistically significant, and dose-dependent lowering of both PCSK9 and LDL cholesterol levels.
Read our Press Release ALN-PCS Phase I Data Presentation (3.6MB PPT) Listen to Conference CallDecember 16, 2011
Podcast: ALN-TTR Phase I Preliminary Results
We recently presented preliminary clinical results for our Phase I study of ALN-TTR01 at the International Symposium on Familial Amyloidotic Polyneuropathy. In this new podcast, Dinah Sah, Ph.D., VP of Research and lead for the ALN-TTR program, discusses the ALN-TTR01 Phase I results she presented at the Symposium, late November. (Length 00:19:32)
Listen to the podcast (22.9 MB mp3) ALN-TTR01 PhI Prelim Results (821 KB PPT)December 13, 2011
Alnylam Scientists Present New Data on RNAi Therapeutics at 53rd ASH Annual Meeting
In December 2011, our scientists presented multiple posters and presentations at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego, CA. We shared data from two programs within our “Alnylam 5×15” product pipeline, including pre-clinical data from ALN-APC, an RNAi therapeutic targeting protein C for the treatment of hemophilia,…
View the refractory anemia presentation (680 KB PPT) View the hemophilia poster (1.88 MB PDF) View the beta-thalassemia poster (112 KB PDF) View the erythropoiesis poster (435 KB PDF) Read our press releaseNovember 21, 2011
ALN-TTR01 Preliminary Phase I Clinical Results
In November 2011, we presented positive preliminary data from our ALN-TTR01 Phase I study at the VIIIth International Symposium on Familial Amyloidotic Polyneuropathy. These data show that administration of ALN-TTR01 resulted in statistically significant reductions in serum TTR protein levels in ATTR patients and demonstrate human proof of concept for RNAi therapeutics.
Read our press release ALN-TTR01 PhI Prelim Results (821 KB PPT) Listen to replay of conference call (7.1 MB mp3July 24, 2011
“Alnylam 5×15″ Product Strategy
In January 2011, we were very excited to launch our Alnylam 5×15™RNAi therapeutic product strategy. Alnylam 5×15 was established to focus on the development and commercialization of novel RNAi therapeutics addressing genetically defined diseases with major unmet medical need.
Read our press release Listen to our CEO discuss our 5×15 Strategy (4.7MB MP3) Rare Disease Day podcast (7.2MB MP3)January 20, 2011
“Alnylam 5×15″ Podcast
Alnylam’s CEO, John Maraganore, discusses Alnylam 5×15 product strategy focused on the development of innovative RNAi therapeutics for genetically defined diseases addressing major unmet medical needs.
Listen to the Podcast (8MB MP3)